查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1553641

兒科疫苗市場規模、佔有率、趨勢分析報告：按類型、技術、應用、地區、細分市場預測，2024-2030 年

Pediatric Vaccines Market Size, Share & Trends Analysis Report By Type (Monovalent, Multivalent), By Technology (Live Attenuated Vaccines), By Application (Cancer), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

兒科疫苗市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，全球兒科疫苗市場規模將達到494.6億美元，複合年成長率為4.1%。

疫苗開發和新產品推出的新興市場開拓是市場的主要促進因素。

公司增加投資以獲得更大的市場佔有率預計將推動成長。導致投資增加的因素包括新興市場強勁的成長前景、醫生強制執行的兒童免疫計劃以及聯合國兒童基金會和世界衛生組織等醫療保健組織主導的宣傳計劃。此外，政府加強提高免疫意識也有望推動兒科疫苗市場的發展。

新型佐劑和治療性疫苗的開發進展預計將在預測期內推動成長。正在進行的針對體內特定作用機制的新型分子的研究旨在提供針對癌症和茲卡病毒感染疾病等致命疾病的免疫力。例如，2016年6月，Inovio Pharmaceuticals, Inc.宣布啟動名為GLS-5700的茲卡病毒DNA疫苗的I期臨床試驗。

兒科疫苗市場報告亮點

  • 從類型來看，由於高使用率和政府活性化研發活動等因素，單價疫苗已成為最大的市場區隔。
  • 就 2023 年的銷售額而言，結合疫苗將構成壓倒性的技術領域。這些疫苗的高採用率和感染疾病病率的增加是兒科疫苗市場的主導因素。
  • 從應用來看，麻疹-流行性腮腺炎-德國麻疹(MMR) 領域預計在預測期內將以 6.1% 的最快複合年成長率成長。這是因為麻疹、腮腺炎和德國麻疹病例持續存在，這是免疫覆蓋率低地區未接種疫苗的兒童的特徵。
  • 2023 年，北美地區佔據最大的銷售佔有率。北美在兒科疫苗市場的主導地位是由於行業巨頭在當地的存在以及廣泛的研發活動等因素。
  • 由於感染疾病的流行和目標人口的增加，預計亞太地區在未來十年將出現良好的成長。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章兒科疫苗市場變數、趨勢和範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 兒科疫苗市場分析工具
    • 波特的分析
    • PESTEL分析

第4章兒科疫苗市場：按類型估計和趨勢分析

  • 細分儀表板
  • 兒科疫苗市場：2023 年和 2030 年按類型分類的變化分析
  • 單價
  • 多效價的

第5章兒科疫苗市場：技術估算與趨勢分析

  • 細分儀表板
  • 兒科疫苗市場：2023 年和 2030 年技術變化分析
  • 減毒活疫苗
  • 去活化疫苗
  • 次單位疫苗
  • 類毒素疫苗
  • 結合疫苗
  • 其他

第6章兒科疫苗市場：按應用估算和趨勢分析

  • 細分儀表板
  • 兒科疫苗市場：2023 年和 2030 年按應用分類的變化分析
  • 感染疾病
  • 癌症
  • 過敏
  • 肺炎鏈球菌感染
  • 流感
  • 麻疹、德國麻疹、腮腺炎 (MMR)
  • 其他用途

第7章兒科疫苗市場：區域估計和趨勢分析

  • 2023 年及 2030 年兒科疫苗市場佔有率（按地區）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 科威特

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • AstraZeneca
    • Sanofi
    • GSK plc
    • Pfizer, Inc.
    • Zydus Group
    • Indian Immunologicals Ltd.
    • Serum Institute of India Pvt. Ltd.
    • Panacea Biotec
    • SINOVAC
    • BIO-MED
簡介目錄
Product Code: GVR-2-68038-279-2

Pediatric Vaccines Market Growth & Trends:

The global pediatric vaccines market size is expected to reach USD 49.46 billion by 2030, registering a CAGR of 4.1%, according to a new report by Grand View Research, Inc. Advancements in development of vaccines and new product launches are some of the major drivers of the market.

Increase in investments by companies to capture a larger market share is anticipated to propel growth. Some of the factors attributed to increase in investment are high growth prospects in the emerging market, immunization schedule mandated by doctors for children, and awareness programs led by UNICEF, WHO, and other healthcare organizations. Furthermore, increase in number of government initiatives for raising awareness about immunization is expected to boost the market for pediatric vaccines.

Advancements in development of novel adjuvants and therapeutic vaccines are expected to drive growth during the forecast period. Ongoing research in novel molecules targeted at specific mechanisms of action in the body is aimed at providing immunity against fatal diseases such as cancer and Zika virus disease. For instance, in June 2016, Inovio Pharmaceuticals, Inc. announced the initiation of phase I clinical trial for their Zika DNA vaccine named GLS-5700.

Pediatric Vaccines Market Report Highlights:

  • By type, monovalent emerged as the largest segment due to factors such as high usage and increase in initiatives for R&D activities supported by various governments.
  • Conjugate vaccines formed the dominant technology segment in terms of revenue in 2023. Higher adoption of these vaccines and increase in prevalence of infectious diseases contribute to its lead in the market for pediatric vaccines.
  • By application, the measles, mumps, and rubella (MMR) segment is projected to grow at the fastest CAGR of 6.1% over the forecast period. This is attributable to the fact that there are still cases of measles, mumps, and rubella which are characteristics of children who have not been vaccinated in areas with poor coverage.
  • North America held the largest revenue share in 2023. Its dominance in the market for pediatric vaccines is owing to factors such as local presence of major players in the industry and extensive R&D activities.
  • The Asia Pacific region is anticipated to witness lucrative growth over the next decade due to increase in prevalence of infectious diseases and a large target population.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Pediatric Vaccines Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Pediatric Vaccines Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Pediatric Vaccines Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Pediatric Vaccines Market: Type Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Monovalent
    • 4.3.1. Monovalent Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Multivalent
    • 4.4.1. Multivalent Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Pediatric Vaccines Market: Technology Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Pediatric Vaccines Market: Technology Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Live Attenuated Vaccines
    • 5.3.1. Live Attenuated Vaccines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Inactivated Vaccines
    • 5.4.1. Inactivated Vaccines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Subunit Vaccines
    • 5.5.1. Subunit Vaccines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Toxoid Vaccines
    • 5.6.1. Toxoid Vaccines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Conjugate Vaccines
    • 5.7.1. Conjugate Vaccines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Pediatric Vaccines Market: Application Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Pediatric Vaccines Market: Application Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Infectious Disease
    • 6.3.1. Infectious Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Cancer
    • 6.4.1. Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Allergy
    • 6.5.1. Allergy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Pneumococcal Diseases
    • 6.6.1. Pneumococcal Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Influenza
    • 6.7.1. Influenza Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Measles, Mumps, and Rubella (MMR)
    • 6.8.1. Measles, Mumps, and Rubella (MMR) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.9. Other Application
    • 6.9.1. Other Application Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Pediatric Vaccines Market: Regional Estimates & Trend Analysis

  • 7.1. Pediatric Vaccines Market Share, By Region, 2023 & 2030 (USD Million)
  • 7.2. North America
    • 7.2.1. North America Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. South Africa
      • 7.6.4.1. South Africa Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Pediatric Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. AstraZeneca
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Sanofi
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. GSK plc
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Pfizer, Inc.
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Zydus Group
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Indian Immunologicals Ltd.
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Serum Institute of India Pvt. Ltd.
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Panacea Biotec
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. SINOVAC
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. BIO-MED
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives